HCW Biologics Says If No Additional Financings Occur After Date Of Issuance, We Believe Relevant Conditions That Brought About Substantial Doubt Can Be Alleviated If We Implement Plan That Includes Certain Adjustments To Strategic And Operating Plans, Such As Cutting Back On Number Of Investigative Studies And Phase 2 Clinical Trials We Initiate; Reducing Salaries And Other Spending, And Limiting Amount Of Cash Used To Reduce Accounts Payable, As Well As Other Adjustments To Alleviate Substantial Doubt
$HCWB
Biotechnology: Pharmaceutical Preparations
Health Care
HCW Biologics Says If No Additional Financings Occur After Date Of Issuance, We Believe Relevant Conditions That Brought About Substantial Doubt Can Be Alleviated If We Implement Plan That Includes Certain Adjustments To Strategic And Operating Plans, Such As Cutting Back On Number Of Investigative Studies And Phase 2 Clinical Trials We Initiate; Reducing Salaries And Other Spending, And Limiting Amount Of Cash Used To Reduce Accounts Payable, As Well As Other Adjustments To Alleviate Substantial Doubt